MedTrace Logo

Efficacy Study to Evaluate the Effect of New Antiviral Drugs on HCV Infection.

NCT02950870 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 75

Last updated 2016-11-01

No results posted yet for this study

Summary

The purpose of this study is to determinate the AMH levels before and after antiviral therapy with Ombitasvir-Paritaprevir-Ritonavir and Dasabuvir in comparison with age-matched HCV-positive women not undergoing antiviral treatment.

Conditions

  • Chronic Hepatitis, C Virus

Interventions

DRUG

Ombitasvir-Paritaprevir-Ritonavir

The patient will be treated daily with Ombitasvir-Paritaprevir-Ritonavir 25/150/100 mg total dose

DRUG

Dasabuvir

The patient will be treated daily with Dasubavir 500 mg total dose

DRUG

Ribavirin

Patients will be treated with ribavirin if necessary.

Sponsors & Collaborators

  • University of Modena and Reggio Emilia

    lead OTHER

Principal Investigators

  • ERICA VILLA, Prof. · Gastroenterology Unit

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
35 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-12-31
Primary Completion
2017-12-31
Completion
2019-12-31

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02950870 on ClinicalTrials.gov